Antiplatelet Agent

Doctors must prescribe heartburn and acidity pills in lowest possible doses and for shortest time to patients to ward off potential side effects, researchers warn.

Ranbaxy Laboratories has launched a generic version of Prasugrel in India. The product, called Prasita, is an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Prasita is solely marketed by Ranbaxy in India.Following the April 2009 launch of Olvan...

Ranbaxy Laboratories launches antiplatelet agent Prasugrel in India Ranbaxy Laboratories has launched a generic version of Prasugrel in India. The product, called Prasita, is an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Prasita is...

Doctors must prescribe heartburn and acidity pills in lowest possible doses and for shortest time to patients to ward off potential side effects, researchers warn.

Ranbaxy Laboratories has launched a generic version of Prasugrel in India. The product, called Prasita, is an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Prasita is solely marketed by Ranbaxy in India.Following the April 2009 launch of Olvan...

Ranbaxy Laboratories launches antiplatelet agent Prasugrel in India Ranbaxy Laboratories has launched a generic version of Prasugrel in India. The product, called Prasita, is an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Prasita is...